Patents by Inventor Horst Dieter Ambrosi

Horst Dieter Ambrosi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11820756
    Abstract: The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to uses of said compound(s), including the use as a medicament.
    Type: Grant
    Filed: January 18, 2022
    Date of Patent: November 21, 2023
    Assignee: PHARVARIS NETHERLANDS B.V.
    Inventors: Christoph Gibson, Joern Saupe, Horst-Dieter Ambrosi, Lars Ole Haustedt
  • Publication number: 20220289730
    Abstract: The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to said compound(s) for use as in a method of treating a skin disorder; eye disease; ear disease; mouth, throat and respiratory disease; gastrointestinal disease; liver, gallbladder and pancreatic disease; urinary tract and kidney disease; disease of male genitale organs and female genitale organs; disease of the hormone system; metabolic disease; cardiovascular disease; blood disease; lymphatic disease; disorder of the central nervous system; brain disorder; musculoskeletal system disease; allergy disorder; pain; infectious disease; inflammatory disorder; injury; immunology disorder; cancer; hereditary disease; or edema.
    Type: Application
    Filed: May 25, 2020
    Publication date: September 15, 2022
    Inventors: Christoph GIBSON, Joern SAUPE, Horst-Dieter AMBROSI, Lars Ole HAUSTEDT
  • Publication number: 20220135542
    Abstract: The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to said compound(s) for use as in a method of treating a skin disorder; eye disease; ear disease; mouth, throat and respiratory disease; gastrointestinal disease; liver, gallbladder and pancreatic disease; urinary tract and kidney disease; disease of male genitale organs and female genitale organs; disease of the hormone system; metabolic disease; cardiovascular disease; blood disease; lymphatic disease; disorder of the central nervous system; brain disorder; musculoskeletal system disease; allergy disorder; pain; infectious disease; inflammatory disorder; injury; immunology disorder; cancer; hereditary disease; or edema.
    Type: Application
    Filed: May 25, 2020
    Publication date: May 5, 2022
    Inventors: Christoph GIBSON, Joern SAUPE, Horst-Dieter AMBROSI, Lars Ole HAUSTED
  • Publication number: 20220135543
    Abstract: The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to uses of said compound(s), including the use as a medicament.
    Type: Application
    Filed: January 18, 2022
    Publication date: May 5, 2022
    Inventors: Christoph GIBSON, Joern SAUPE, Horst-Dieter AMBROSI, Lars Ole HAUSTEDT
  • Patent number: 11261173
    Abstract: The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to uses of said compound(s), including the use as a medicament.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: March 1, 2022
    Assignee: PHARVARIS NETHERLANDS B.V.
    Inventors: Christoph Gibson, Joern Saupe, Horst-Dieter Ambrosi, Lars Ole Haustedt
  • Publication number: 20210017158
    Abstract: The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to uses of said compound(s), including the use as a medicament.
    Type: Application
    Filed: September 25, 2020
    Publication date: January 21, 2021
    Inventors: Christoph GIBSON, Joern SAUPE, Horst-Dieter AMBROSI, Lars Ole HAUSTEDT
  • Patent number: 10836748
    Abstract: The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to uses of said compound(s), including the use as a medicament.
    Type: Grant
    Filed: April 28, 2020
    Date of Patent: November 17, 2020
    Assignee: Pharvaris Netherlands B.V.
    Inventors: Christoph Gibson, Joern Saupe, Horst-Dieter Ambrosi, Lars Ole Haustedt
  • Publication number: 20200255405
    Abstract: The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to uses of said compound(s), including the use as a medicament.
    Type: Application
    Filed: April 28, 2020
    Publication date: August 13, 2020
    Inventors: Christoph GIBSON, Joern SAUPE, Horst-Dieter AMBROSI, Lars Ole HAUSTEDT
  • Publication number: 20130035321
    Abstract: In one aspect, the instant invention provides novel compounds and pharmaceutical compositions useful for treating proliferative diseases such as cancer. In another aspect, the invention provides methods of using certain compounds in the treatment of proliferative diseases such as cancer. In particular, the instant invention provides methods of treating ocular cancer (e.g., retinoblastoma) using intraarterial infusion to administer inventive compounds locally to the eye of a subject with an ocular cancer.
    Type: Application
    Filed: December 1, 2010
    Publication date: February 7, 2013
    Applicants: AnalytiCon Discovery GmbH, Sloan-Kettering Institute for Cancer Research
    Inventors: Hakim Djaballah, Christophe Antczak, David H. Abramson, Horst-Dieter Ambrosi, Karsten Siems, Thorsten Genski
  • Patent number: 6583265
    Abstract: The present invention relates to novel cyclosporins, processes for their preparation, their use as pharmaceuticals and pharmaceutical compositions comprising them. The novel cyclosporins are represented by the compound of formula I or a pharmaceutically acceptable salt thereof, wherein the letters A to L represent residues of amino acids.
    Type: Grant
    Filed: January 8, 2001
    Date of Patent: June 24, 2003
    Assignee: C-Chem AG
    Inventors: Ernst Ellmerer-Müller, Dagmar Brössner, Najib Maslouh, Horst Dieter Ambrosi, Gerhard Jas, Gunter Fischer